The Complete Guide to Gut Signals That Control Hunger and Fullness

Multiple gut-derived peptide signals (CCK, GLP-1, PYY, ghrelin, oxyntomodulin) control meal-to-meal satiety while long-term fat signals (leptin, insulin) regulate body weight — an integrated two-tier system.

Drazen, Deborah L et al.·Current opinion in clinical nutrition and metabolic care·2003·Strong EvidenceReview
RPEP-00813ReviewStrong Evidence2003RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Strong Evidence
Sample
Not reported

What This Study Found

Satiety is controlled by a two-tier peripheral signaling system: short-term gut peptides (CCK, GLP-1, PYY, ghrelin, oxyntomodulin) for meal control and long-term adiposity signals (leptin, insulin) for body weight regulation, integrated by brainstem and hypothalamic circuits.

Key Numbers

How They Did This

Comprehensive review of all peripheral satiety and hunger signals, their receptors, neural pathways, and integration in central appetite circuits.

Why This Research Matters

This review describes the complete signaling architecture that modern obesity drugs target. GLP-1 agonists (semaglutide) work through one of the many pathways described here.

The Bigger Picture

Understanding the full appetite signaling network reveals why single-target drugs have limited weight loss. The most effective future treatments may combine signals from multiple tiers.

What This Study Doesn't Tell Us

Review from 2003. Some signals described were still being characterized. The relative importance of each signal for human obesity treatment was debated.

Questions This Raises

  • ?Can multi-signal targeting achieve greater weight loss than GLP-1 alone?
  • ?Which combination of gut peptide mimetics would be most effective?
  • ?Does chronic obesity alter the sensitivity of these signaling pathways?

Trust & Context

Key Stat:
Two-tier system Meal-by-meal gut signals + long-term fat signals = the complete appetite control architecture that modern obesity drugs target
Evidence Grade:
Strong evidence from a comprehensive review synthesizing decades of appetite physiology research.
Study Age:
Published in 2003. This framework has been validated by the clinical success of GLP-1 agonists (semaglutide) and combined GLP-1/GIP drugs (tirzepatide).
Original Title:
Peripheral signals in the control of satiety and hunger.
Published In:
Current opinion in clinical nutrition and metabolic care, 6(6), 621-9 (2003)
Database ID:
RPEP-00813

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Why is appetite so complex?

Because survival depends on eating the right amount. The body uses multiple overlapping signals — from the gut, fat tissue, and brain — to ensure you eat enough but not too much. Each signal provides different information.

How do current obesity drugs fit in?

Semaglutide (Ozempic) mimics GLP-1, just one of the many gut peptide signals described here. Newer drugs like tirzepatide target two signals (GLP-1 + GIP). Future drugs may target even more for greater effectiveness.

Read More on RethinkPeptides

Cite This Study

RPEP-00813·https://rethinkpeptides.com/research/RPEP-00813

APA

Drazen, Deborah L; Woods, Stephen C. (2003). Peripheral signals in the control of satiety and hunger.. Current opinion in clinical nutrition and metabolic care, 6(6), 621-9.

MLA

Drazen, Deborah L, et al. "Peripheral signals in the control of satiety and hunger.." Current opinion in clinical nutrition and metabolic care, 2003.

RethinkPeptides

RethinkPeptides Research Database. "Peripheral signals in the control of satiety and hunger." RPEP-00813. Retrieved from https://rethinkpeptides.com/research/drazen-2003-peripheral-signals-in-the

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.